Global Hematology Drugs Market – Industry Trends and Forecast to 2029

Global Hematology Drugs Market, By Drugs Class (Anticoagulants, Antiplatelet, Iron Supplements, Anti- thymocyte Globulins, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) Industry Trends and Forecast to 2029.

 Market Analysis and Insights

Hematologic therapies, including medication represent molecular understanding of the disease pathophysiology. The hematology drugs acts as a treatment targeted precisely at the known aberration. Hematology is used for diagnosis, treatment and study of blood and disorders related to blood.

Global Hematology Drugs Market was valued at USD 85606.01 million in 2021 and is expected to reach USD 165631.48 million by 2029, registering a CAGR of 8.60% during the forecast period of 2022-2029. “Hospitals” accounts for the most prominent end user segment in the respective market owing to the rise in the number of blood disorder cases. The market report curated by DBMR research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Hematology is defined as a branch of medical science that is mainly concerned with the diagnosis, treatment and study of blood and disorders. It consists of treatment of blood disorders, including malignancies and leukemia, among others. The hematology drugs refer to the type of drugs that are utilized for treating hematologic disorders constituting of an extraordinary array of agents. These include therapy for bleeding diatheses, hematologic malignancies, anemias and thromboembolism.

Report Scope and Market Segmentation

Hematology Drugs Market Dynamics

Drivers

• Prevalence of Blood Disorders

The rise in prevalence of blood and disorders, such as malignancies and leukemia and types of lymphoma, sickle-cell anemia and haemophilia, among others across the globe acts as one of the major factor driving the growth of hematology drugs market.

• Adaptation of Unhealthy Lifestyle

The adaptation of unhealthy lifestyle, increased stress in daily life and malnutrition and family history with hematological disease accelerate the market growth.

• Increase In Mergers and Acquisitions

The increase in the number of mergers and acquisitions among manufacturers and research organizations to provide efficient medical care to patients and generate significant revenues by their sales options results in the expansion of the market.

Additionally, development in technology, large patient base and superior technology, increase in demand for effective therapies and surge in healthcare expenditure positively affect the ophthalmic drugs market.

Opportunities

Furthermore, development and manufacturing of different combination of hematology drugs extends profitable opportunities to the market players in the forecast period of 2022 to 2029. Also, research to optimize and expand the applications across hematologic indications will escalate the growth of ophthalmic drugs market.

Restraints/Challenges

On the other hand, high cost for the medicine is expected to obstruct the market growth. The stringent regulatory policies for the approval of new treatment is projected to challenge the hematology drugs market in the forecast period of 2022-2029.

This hematology drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on hematology drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

World Federation of Hemophilia’s (WFH) 2018 statistics report of approximately 440,000 people being affected with haemophilia. Out of these around 173,000 people were diagnosed with hemophilia A or B in 2017 globally. The report also states that prevalence of anemia in children was around 45%, and is rapidly increasing.

The hematology drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Covid-19 Impact on Hematology Drugs Market

The COVID 19 had both positive and negative impact on the hematology drugs market owing to the rise in cases of conjunctivitis among population. The need of immediate treatment for the blood related disorders escalated during this pandemic. However, global shut down of numerous companies due to the implementation of lockdowns by government and supply chain disruptions greatly impacted the market. In the post-COVID scenario, the supply chain disruptions and logistics are being eased in that assists in the growth of hematology drugs market.

Global Hematology Drugs Market

The hematology drugs market is segmented on the basis of drug class, route of administration, end-users and distribution channel.The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drugs Class

• Anticoagulants
• Antiplatelet
• Iron Supplements
• Anti- Thymocyte Globulins
• Others

On the basis of drugs class, the hematology drugs market is segmented into anticoagulants, antiplatelet, iron supplements, anti- thymocyte globulins and others.

Route of Administration

• Oral
• Parenteral
• Others

Route of administration segment of hematology drugs market is segmented into oral, parenteral and others.

End-Users

• Hospitals
• Specialty Clinics
• Others

On the basis of end-users, the hematology drugs market is segmented into hospitals, specialty clinics and others.

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Others

On the basis of distribution channel, hematology drugs market has also been segmented into hospital pharmacy, retail pharmacy others.

Pipeline Analysis

Anticoagulants are widely utilized for preventing blood clots, and are given to patients at a high risk of getting clots. They decline chances of developing serious conditions such as strokes and heart attacks. Novartis AG, GlaxoSmithKline Plc., Teva Pharmaceuticals Industries Ltd., Sanofi, F. Hoffmann-La Roche Ltd., AbbVie Inc., GlaxoSmithKline Plc., among others are some of the manufacturers involved with the development of hematology drugs.

Hematology Drugs Market Regional Analysis/Insights

The hematology drugs market is analysed and market size insights and trends are provided by country, drug class, route of administration, end-users and distribution channel as referenced above.

The countries covered in the hematology drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the hematology drugs market due to the availability of key manufacture of the product high consumer awareness within the region.

Asia-Pacific is expected to witness high growth during the forecast period of 2022 to 2029 because of the prevalence of iron deficiency anaemia and related disorders in the region.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Hematology Drugs Market Share Analysis

The hematology drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to hematology drugs market.

Some of the major players operating in the hematology drugs market are

• Novartis AG (Switzerland)
• GlaxoSmithKline Plc. (UK)
• Teva Pharmaceuticals Industries Ltd. (Israel)
• Sanofi (France)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• AbbVie Inc. (US)
• Pfizer Inc. (US)
• Bristol-Myers Squibb Company (US)
• Dr. Reddy’s Laboratories Ltd (India)
• Mylan N.V. (US)